Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

By F. Cecchi, Iacopo Olivotto, R. Gistri, R. Lorenzoni, G. Chiriatti, P. Camici. New England Journal of Medicine, 2003

745 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/391f911acfdd35d70213ea3c3cc6224f7ed46a21

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. B. Maron
2. Steve R. Ommen
3. M. Maron
4. P. Spirito
5. C. Semsarian
6. Iacopo Olivotto

In Radiology, Nuclear Medicine and Imaging

1. M. D. Di Carli
2. V. Taqueti

Citations in the corpus

• Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. (2014, background): “Such symptoms can be accompanied by chest pain (atypical or typical of atherosclerotic CAD), which are likely related to microvascular ischemia (79,80).”
• Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. (2009, background): “Outcome data on PET MPI is scarce, and outcome data on CFR is limited to subgroups of patients such as those with non-ischemic dilative [7] or hypertrophic cardiomyopathy [8].”
• Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. (2018, background): “The latter group includes idiopathic (37,38), hypertrophic (71,72), infiltrative (73) and stress (74,75) cardiomyopathies.”